Rachel Toth

Rachel Toth

Auto-generated profile, based on publicly available information

Rachel Toth

MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Science Advances
Verified
Journal Article
Open access
OAOdetta Antico
Odetta Antico
AOAlban Ordureau
Alban Ordureau
MSMichael Stevens
Michael Stevens
FSFrancois Singh
Francois Singh
RNRaja S. Nirujogi
Raja S. Nirujogi
MMMiratul M. K. Muqit
Miratul M. K. Muqit
Identification of neuronal targets of PD-linked enzyme Parkin by quantitative ubiquitin-based proteomics.

7 June 2024 in Science Advances
Verified
Journal Article
Open access
OROlawale G. Raimi
Olawale G. Raimi
HOHina Ojha
Hina Ojha
KEKenneth Ehses
Kenneth Ehses
VDVerena Dederer
Verena Dederer
SLSven M. Lange
Sven M. Lange
MMMiratul M. K. Muqit
Miratul M. K. Muqit
Loss-of-function mutations in PTEN-induced kinase 1 (PINK1) are a frequent cause of early-onset Parkinson’s disease (PD). Stabilization of PINK1 at the translocase of outer membrane (TOM) complex of damaged mitochondria is critical for its activation. The mechanism of how PINK1 is activated in the TOM complex is unclear. Here, we report that co-expression of human PINK1 and all seven TOM subunits in Saccharomyces cerevisiae is sufficient for PINK1 activation. We use this reconstitution system to systematically assess the role of each TOM subunit toward PINK1 activation. We unambiguously demonstrate that the TOM20 and TOM70 receptor subunits are required for optimal PINK1 activation and map their sites of interaction with PINK1 using AlphaFold structural modeling and mutagenesis. We also demonstrate an essential role of the pore-containing subunit TOM40 and its structurally associated subunits TOM7 and TOM22 for PINK1 activation. These findings will aid in the development of small-molecule activators of PINK1 as a therapeutic strategy for PD.

20 March 2023 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
MSMichael U Stevens
Michael U Stevens
NCNathalie Croteau
Nathalie Croteau
MEMohamed Eldeeb
Mohamed Eldeeb
OAOdetta Antico
Odetta Antico
ZZZhi Wei Zeng
Zhi Wei Zeng
JTJean-François Trempe
Jean-François Trempe
Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.

15 May 2023 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
MGMateusz Gregorczyk
Mateusz Gregorczyk
GPGraziana Pastore
Graziana Pastore
IMIvan Muñoz
Ivan Muñoz
TCThomas Carroll
Thomas Carroll
JSJohanna Streubel
Johanna Streubel
JRJohn Rouse
John Rouse
The NEK1 kinase controls ciliogenesis, mitosis, and DNA repair, andNEK1mutations cause human diseases including axial spondylometaphyseal dysplasia and amyotrophic lateral sclerosis.C21ORF2mutations cause a similar pattern of human diseases, suggesting close functional links withNEK1. Here, we report that endogenous NEK1 and C21ORF2 form a tight complex in human cells. A C21ORF2 interaction domain “CID” at the C-terminus of NEK1 is necessary for its association with C21ORF2 in cells, and pathogenic mutations in this region disrupt the complex. AlphaFold modelling predicts an extended binding interface between a leucine-rich repeat domain in C21ORF2 and the NEK1–CID, and our model may explain why pathogenic mutations perturb the complex. We show that NEK1 mutations that inhibit kinase activity or weaken its association with C21ORF2 severely compromise ciliogenesis, and that C21ORF2, like NEK1 is required for homologous recombination. These data enhance our understanding of how the NEK1 kinase is regulated, and they shed light on NEK1–C21ORF2–associated diseases.

9 May 2025 in Science Advances
Verified
Journal Article
Open access
PSPawan K. Singh
Pawan K. Singh
SAShalini Agarwal
Shalini Agarwal
IVIlaria Volpi
Ilaria Volpi
LWLéa P. Wilhelm
Léa P. Wilhelm
GBGiada Becchi
Giada Becchi
MMMiratul M. K. Muqit
Miratul M. K. Muqit
Loss-of-function mutations in the PINK1 kinase lead to early-onset Parkinson’s disease (PD). PINK1 is activated by mitochondrial damage to phosphorylate ubiquitin and Parkin, triggering mitophagy. PINK1 also indirectly phosphorylates Rab GTPases, such as Rab8A. Using an siRNA library targeting human Ser/Thr kinases in HeLa cells, we identified EIF2AK1 [heme-regulated inhibitor (HRI) kinase], a branch of the integrated stress response (ISR), as a negative regulator of PINK1. EIF2AK1 knockdown enhances mitochondrial depolarization–induced PINK1 stabilization and phosphorylation of ubiquitin and Rab8A. These results were confirmed in SK-OV-3, U2OS, and ARPE-19 cells. Knockdown of DELE1, an activator of EIF2AK1, produced similar effects. Notably, the ISR inhibitor ISRIB also enhanced PINK1 activation. In human cells with mito-QC mitophagy reporters, EIF2AK1 knockdown or ISRIB treatment increased PINK1-dependent mitophagy without affecting deferiprone-induced mitophagy. These findings suggest that the DELE1-EIF2AK1 ISR pathway is a negative regulator of PINK1-dependent mitophagy. Further evaluation in PD-relevant models is needed to assess the therapeutic potential of targeting this pathway.

12 July 2022 in Science Signaling
Verified
Journal Article
Open access
ASAnna Segarra-Fas
Anna Segarra-Fas
CECarmen Espejo-Serrano
Carmen Espejo-Serrano
Francisco BustosFrancisco Bustos
Francisco Bustos
HZHoujiang Zhou
Houjiang Zhou
FWFeng Wang
Feng Wang
GFGreg M. Findlay
Greg M. Findlay
The E3 ubiquitin ligase RNF12 plays essential roles during development, and the gene encoding it, RLIM , is mutated in the X-linked human developmental disorder Tonne-Kalscheuer syndrome (TOKAS). Substrates of RNF12 include transcriptional regulators such as the pluripotency-associated transcriptional repressor REX1. Using global quantitative proteomics in male mouse embryonic stem cells, we identified the deubiquitylase USP26 as a putative downstream target of RNF12 activity. RNF12 relieved REX1-mediated repression of Usp26 , leading to an increase in USP26 abundance and the formation of RNF12-USP26 complexes. Interaction with USP26 prevented RNF12 autoubiquitylation and proteasomal degradation, thereby establishing a transcriptional feed-forward loop that amplified RNF12-dependent derepression of REX1 targets. We showed that the RNF12-USP26 axis operated specifically in mouse testes and was required for the expression of gametogenesis genes and for germ cell differentiation in vitro. Furthermore, this RNF12-USP26 axis was disrupted by RLIM and USP26 variants found in TOKAS and infertility patients, respectively. This work reveals synergy within the ubiquitylation cycle that controls a key developmental process in gametogenesis and that is disrupted in human genetic disorders.